Exclusive: Biogen president fears CMS will finalize restrictive coverage decision for Aduhelm, preps plans to flood NCD with comments
While lamenting yesterday’s proposed national coverage decision for its controversial Alzheimer’s drug, Biogen’s US president Alisha Alaimo pledged to flood CMS with comments over the next 30 days in an attempt to ensure the final version does not reflect Tuesday’s draft, according to an internal email reviewed by Endpoints News.
“We were prepared for the range of scenarios. Unfortunately, this is one of the most restrictive options CMS could have chosen,” Alaimo said in an email to staff on Wednesday. “If this draft becomes final in April, it will significantly limit Medicare reimbursement for Aduhelm and future therapies in this class.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.